The purpose was to assess factors associated with the administration of chemotherapy and their relation to survival at a population-based level.
reported to influence the administration of adjuvant chemotherapy [10] .
Since the mid-1990s, adjuvant chemotherapy has been recommended in Dutch treatment guidelines for stage III colon cancer patients (Table 1 ) [11] . In order to evaluate adherence to these guidelines in southern Netherlands in recent years, we assessed factors associated with the administration of chemotherapy. Variation between hospitals was assessed to differentiate between early and late adapters for adjuvant chemotherapy administration. In addition, we determined to what extent these factors and the introduction of new chemotherapeutic agents were related to survival at a population-based level.
part of The Netherlands with 2.4 million inhabitants. The ECR is served by 10 community hospitals, 6 pathology departments, and 2 radiotherapy institutes. Information on patient characteristics, such as gender, date of birth, and postal code, and tumor characteristics, such as date of diagnosis, tumor type, subsite (International Classification of Diseases for Oncology [12] ), histology, stage (tumor-lymph node-metastasis classification [13] ), grade, and treatment, is obtained routinely from the medical records [14] . In addition, information on comorbidity on the basis of the Charlson comorbidity index was routinely collected [15] . SES, on the basis of individual fiscal data on the economic value of the home and household income, was provided at an aggregated level for each postal code [16] . The quality of the data is high, due to thorough training of the registration clerks and a variety of computerized consistency checks at regional and national levels. Completeness is estimated to be at least 95% [17] . For the present study, all cases with primary colon cancer (C18.0-C18.7) registered from 2001 to 2007 in the area of the ECR were included (N = 1637). Age was divided into three groups: <65, 65-74, and ‡75 years. Follow-up of vital status of all patients was complete up to 1 January 2008. In addition to passive follow-up via the hospitals, the information was actively obtained from civil municipal registries and the Central Bureau for Genealogy.
Proportions of patients who received chemotherapy were described per age group and according to gender, comorbidity, SES, stage, tumor grade, number of examined lymph nodes, period of diagnosis, and hospital. Differences in chemotherapy administration between subgroups were tested by means of a chi-square test or a Cochran-Armitage trend test. Multivariable logistic regression analysis was conducted for the following determinants of chemotherapy administration: age, gender, comorbidity, SES, stage, tumor grade, period of diagnosis, and hospital. Survival time was defined as the time from diagnosis to death or 1 January 2008 for the patients who were still alive. Crude 5-year survival was calculated and a logrank test was carried out to compare survival proportions. A multivariable proportional hazards regression analysis was used to discriminate independent risk factors for death (SAS system 8.2; SAS Institute, Cary, NC). P values <0.05 were considered statistically significant.
results
The proportion of patients with stage III colon cancer (N = 1637) receiving adjuvant chemotherapy decreased with increasing age from 85% for patients <65 years to 68% for those aged 65-74 years and 17% for those ‡75 years (P for trend <0.0001). Patients with comorbidity received chemotherapy less often. A large interhospital variation in chemotherapy use was found for all age groups with the proportion of patients <65 years receiving chemotherapy ranging from 82% to 96%. For patients aged 65-74 years, chemotherapy use ranged from 59% to 78% and among the elderly from 9% to 25%. The differences in administration of chemotherapy persisted throughout all age groups (Table 2 ). Increasing age, female gender, comorbidity, and low SES were associated with less frequent administration of chemotherapy. After adjustment, elderly patients ( ‡75 years), those with comorbidity, and patients with a low SES received chemotherapy less often, while patients with a high stage (IIIC, any T, N2) received chemotherapy more often. Furthermore, significant differences in the administration of chemotherapy were found between hospitals (Table 3) . Similar results were found after stratifying patients according to comorbidity, although younger (<65 years) patients received chemotherapy significantly more often in the groups with and without comorbidity (data not shown).
There was no significant increase in chemotherapy use in the period 2001-2007 in any 5-year age group, although the increase was somewhat larger in the higher age groups; patients aged 70-74 years exhibited the largest increase (18%), while those ‡75 years showed a much smaller increase (8% for 75-79 years and 4% for ‡80 years) ( Figure 1 ). Chemotherapy use changed differently per hospital over time, with large variation between hospitals. Some hospitals exhibited an increase of up to 33% from 2001 to 2007, while others showed a decrease of up to 33% in the same period. Over time, the variation seemed to decrease, although in 2007, the variation still ranged from 38% to 75% between hospitals (data not shown).
A significant effect of chemotherapy was found for patients with colon cancer stage III. For patients receiving chemotherapy, a significant effect of age on survival was found, while this effect could not be demonstrated for patients not receiving chemotherapy ( Figure 2 ). Crude 5-year survival was 47% for patients with colon cancer stage III. Patients receiving adjuvant chemotherapy had a 5-year survival of 62%, while patients not receiving chemotherapy had a survival of 29% (P < 0.0001). Increasing age, comorbidity, higher stage, poor tumor grade, and fewer lymph nodes examined were associated with a worse crude 5-year survival. Chemotherapy was the strongest predictor of survival after adjustment for relevant patient and tumor factors {hazard ratio 0. (Table 5) . Similar overall survival patterns were found after stratification for age, chemotherapy use, or comorbidity (data not shown).
discussion
In this study, we showed that the proportion of stage III colon cancer patients receiving adjuvant chemotherapy decreased with increasing age. Elderly patients ( ‡75 years), those with comorbidity, and patients with a low SES received chemotherapy less frequently. A large between-hospital variation was found in the administration of chemotherapy. Receiving chemotherapy was the strongest predictor of survival in this retrospective study, while older age was no longer It has been shown in previous studies that a lower proportion of elderly patients receive adjuvant chemotherapy [7, 10] . Several reasons are given in literature to explain why elderly patients are less likely to receive adjuvant chemotherapy, including the presence of concomitant diseases, frailty, the absence of supportive caregivers, and a decrease in the patients' general condition and cognitive ability [18] . Elderly patients seem less willing to accept the negative effects of treatment with adjuvant chemotherapy compared with younger patients [19, 20] , resulting in more patient refusal. In addition, the decision of the medical oncologist, which is on the basis of clinical experience plays a role in the choice for adjuvant Annals of Oncology original article chemotherapy. However, several studies have shown that elderly patients equally benefit from adjuvant chemotherapy treatment with similar toxicity levels [8, 9] . In addition, the benefit of adjuvant chemotherapy is strongest in the first 2 years after treatment [21] . In this light, it is important to note that the life expectancy of 80-year-old Dutch men is still 7 years and is even more for Dutch women [3] . Patients presenting with comorbidity received adjuvant chemotherapy less often, which is in agreement with literature [10] . High stage (IIIC, any T, N2) colon cancer patients more frequently received adjuvant chemotherapy, since they are at high risk of recurrence. In view of the good access to health care facilities and the Dutch health insurance system with a coverage of >99% [22] , our finding that patients with a low SES are less likely to receive adjuvant chemotherapy is remarkable. However, our results are in-line with a previous Dutch study [7] . United States population-based studies also reported a negative effect of low SES on adjuvant treatment of colon cancer patients, although it original article Annals of Oncology is smaller than in our study [23, 24] . Patients with a higher SES have a more positive self-rated health [25, 26] , which may affect treatment decision making. In addition, it is possible that patients with a higher SES are more active in terms of seeking more aggressive treatment.
The wide variation in chemotherapy use across hospitals underscores the influence of institutional factors and local practice patterns in determining the use of adjuvant chemotherapy [27] . Physicians generally agree with clinical guidelines recommending adjuvant chemotherapy for stage III colon cancer for relatively young, healthy patients but differ widely on recommendations for patients who are older and sicker [28] . In addition, fast and slow adapters in hospitals for the administration of chemotherapy could partly explain variation in chemotherapy use.
Chemotherapy has a marked independent prognostic impact, as reported in several other population-based studies [29, 30] . Due to the population-based nature of our data, we do not know to what extent the positive prognostic impact was caused by selection of the 'fitter' patients for adjuvant chemotherapy or other factors not included in our analysis. It is likely that frail elderly people, usually having a worse prognosis, receive adjuvant chemotherapy less often, which could have biased our results. This is supported by the smaller survival difference found in randomized clinical trials [8] .
The negative effect of comorbidity on survival is in-line with previous Dutch population-based studies [31, 32] and could jeopardize the benefit of chemotherapy treatment. Apart from chemotherapy, tumor stage and to a lesser extent grade are also well-known predictors of survival of stage III colon cancer [7, 29] . No effect of hospital of diagnosis on survival was found, despite the large variation in administration of chemotherapy between hospitals. This is most likely the result of the relatively small numbers of patients per hospital.
The lack of effect of age in the group of patients not receiving chemotherapy reflects the diversity of this group. It contains some young patients who probably could not be treated with adjuvant chemotherapy due to a weak general condition. The equal 5-year survival of the younger and older group of patients not treated by adjuvant chemotherapy is probably also due to the fact that a relatively large proportion of these older patients was relatively fit, with the advanced age itself or a decline of therapy as the main determinants for not receiving chemotherapy. This accentuates the probable undertreatment of relatively healthy elderly patients, although these retrospective data have to be interpreted cautiously.
There seemed to be a trend toward an increased survival over time. This may be partly related to upstaging since lymph node detection among these patients has improved during the study period [33] . However, survival of patients with colon cancer stage II did not change significantly over time. oxaliplatin on survival cannot be seen yet. Fear for the increased toxicity of these multidrug regimens may have kept oncologists from administering these regimens to elderly patients. Besides, the Dutch clinical guideline indicates that monotherapy capecitabine chemotherapy can be chosen as an alternative treatment in case of aging or comorbidity. Further studies should focus on multidrug less aggressive regimens specifically for the elderly.
In conclusion, adherence to guidelines for adjuvant chemotherapy was still suboptimal in 2007, especially for elderly patients, and differed widely between hospitals. Factors associated with reduced use of chemotherapy are older age, comorbidity, and low SES. Although partly biased by the retrospective nature of our data, chemotherapy was the strongest predictor of survival, while age was no longer significant after correcting for factors affecting survival, indicating undertreatment of elderly patients. To prevent any undertreatment of subgroups of especially elderly patients with colon cancer otherwise fit enough to undergo chemotherapy, some form of geriatric assessment might be helpful in decision making. Awareness of physicians should reduce hospital variation and prevent undertreatment among lower SES patients. 
